Roche licenses KSQ’s PhI cancer small molecule, with cash infusion to help bankroll biotech’s TIL cell therapies

KSQ Therapeutics quickly lined up another Big Pharma partnership, this time allying with Roche in oncology, and it plans to use the cash windfall to fund a clinical entry next year for its internal TIL cell therapies.

The Lexington, MA-based biotech said Thursday it is out-licensing its clinical-stage small molecule…
Click here to view original post